🔗 Share this article

A shadow market for unapproved slimming drugs is propelled by social media fitness personalities and sellers on messaging platforms, according to new investigations.

Investigational Treatment Acquiring Popularity Via Social Media

Retatrutide, which is still in research studies, is being advertised by online personalities for its supposed weight-reducing properties. Followers are encouraged to contact these accounts privately for supplier links, while also receiving discount codes.

Thriving Trade on Social Networks

Additionally, a flourishing trade exists on messaging services, where communities with thousands of members share “before and after” images, injection guides and claims of next-day British shipping. Sellers market the drug there before redirecting buyers to other platforms for transactions.

Learning About The Experimental Drug

Retatrutide is an investigational injectable created by US drugmaker Eli Lilly. The treatment targets three gut hormones – glucagon-like peptide-1, GIP and glucagon. Preliminary studies indicate it could assist patients lose up to a quarter of their total weight. Nicknamed the “triple G”, the drug is being promoted digitally as the successor to Ozempic.

Healthcare Professionals Voice Concerns

However, physicians and chemists have warned that the distribution of what is still an unapproved drug in the UK is worrisome and could result in individuals administering substances of unknown origin.

Some experts said the demand for the experimental drug could be linked to the increasing price of licensed slimming treatments such as Mounjaro.

Legal Position and Enforcement

Selling retatrutide on social media or Telegram is prohibited in the United Kingdom, as it is an unlicensed medication that must not be marketed or distributed for personal consumption under the Human Medicines Regulations 2012.

Several content creators try to sidestep the regulations by calling to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a restricted drug, but advertising and distribution can still violate pharmaceutical, advertising, and consumer regulations, potentially leading to fines, legal action or imprisonment.

Platform Response and Material Removal

According to the social media company, the platform has taken down violative content and banned associated keywords and search suggestions. The organization stated it was committed to keeping the service secure and allocating resources in strengthening compliance measures.

Online Trading Activities

Investigations also discovered communities with up to 9,000 participants selling the experimental drug using Telegram's integrated discovery tool, which operates like a public directory. Entering “retatrutide” immediately displays groups with thousands of members, filled with photos of weight loss, glowing testimonials and detailed instructions for mixing or administering at residence.

Within minutes of joining one community, a seller shared WhatsApp details, where the majority of purchases occur. The seller sent an guidebook and guaranteed shipping within 48 hours. When asked whether the product was genuine, one vendor said: “You can’t be sure.” Another provided a image of a supposed testing documentation. None inquired about weight, medical conditions or past usage.

Item Information and Pricing

Within these groups, posts display dark colored packages with postal service labels, stating to contain new batches. One message read: “It took eight of us to load them this morning.”

Customers can select between dry substance containers, mixed at home with purified liquid, or ready-to-use injectors usually sold at 160 pounds for 20 milligrams. When asked how long a injector should last, sellers give conflicting responses varying between a few weeks to “depends on your body”.

Service Oversight and Safety Actions

A representative for the messaging service said it actively moderated dangerous material on its service including content that promoted the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.

Medical Professional Warnings

“People are administering substances they can’t verify. Even if the science behind this drug is valid, these digital products may not include what they advertise,” said Jason Murphy, the director of pharmaceutical services at a pharmacy service.

Dr Crystal Wyllie of an online medical service linked the increase in demand to current cost increases for authorized slimming drugs such as Mounjaro. “With prices rising, individuals are using social media. But fake treatments are extremely dangerous. You can’t be certain what’s inside or whether the conditions they were produced in was sterile,” she said.

Her staff has previously encountered patients harmed by personal administration from unconfirmed suppliers. “We recognize the frustration, but buying from messaging apps or communication platforms is taking chances with your health,” stated Wyllie. “These substances could be contaminated or improperly measured.”

Producer Position

A spokesperson from the pharmaceutical company stated the substance was in phase 3 clinical trials and had not been evaluated or approved by any government authority anywhere in the world. “Consequently at this point no one can sell [it] for human use,” they explained, noting that any product “misleadingly claiming itself as a company investigational product not yet authorized … may subject patients to potentially serious medical dangers”.